Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study
Updated analysis reveals high overall response rates in patients with Waldenström macroglobulinemia, suggesting Bexobrutideg's potential in B-cell malignancies.
Key Points
Overall response rate reached 85.0% in patients with Waldenström macroglobulinemia, showing significant clinical activity.
Patients demonstrated a median IgM reduction of 79.6%, indicating effective treatment response.
Analysis from an ongoing Phase 1a/b trial assessed safety and preliminary efficacy of Bexobrutideg in B-cell malignancies.
Findings highlight Bexobrutideg's tolerability and efficacy, with ongoing expansion in Phase 1b study.